Corticobasal Degeneration Market

The corticobasal degeneration market has been comprehensively analyzed in IMARC's new report titled "Corticobasal Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Corticobasal degeneration (CBD) refers to a rare neurodegenerative disorder characterized by progressive deterioration of specific areas in the brain, leading to a range of debilitating symptoms. The condition primarily affects the cerebral cortex and the basal ganglia, causing a gradual decline in motor functions and cognitive abilities. The symptoms of the ailment are varied and often include a combination of movement difficulties, such as muscle stiffness, tremors, and loss of coordination, resembling parkinsonism. These motor impairments are typically asymmetric, affecting one side of the body more severely than the other. Additionally, individuals suffering from CBD may experience cognitive changes, such as memory deficits, language difficulties, and impaired executive functions like planning and decision-making. Diagnosing this illness can be challenging due to its overlap with other neurodegenerative disorders. A comprehensive clinical evaluation is crucial, considering both motor and cognitive symptoms. Neuroimaging techniques, such as magnetic resonance imaging (MRI), can reveal specific patterns of brain atrophy that are indicative of CBD.

The escalating incidences of protein abnormalities involving tau and alpha-synuclein, which can lead to the deterioration of brain cells and subsequent motor and cognitive impairments, are primarily driving the corticobasal degeneration market. In addition to this, the inflating utilization of symptom-relieving interventions, such as dopamine-enhancing medications, cholinesterase inhibitors, and botulinum toxin injections to manage the condition's effects, is also creating a positive outlook for the market. Moreover, the widespread adoption of tailored physical and speech therapies, since they can help in boosting muscle tone, mitigating communication challenges, and ameliorating overall motor functions, is further bolstering the market growth. Apart from this, the rising usage of deep brain stimulation procedures which involve the implantation of electrodes to modulate abnormal brain activity and alleviate some of the debilitating indications, is acting as another significant growth-inducing factor. Additionally, the escalating demand for advanced imaging technologies like PET scans and functional MRI, which offer better insights into neural degeneration, is also augmenting the market growth. Furthermore, the emerging popularity of gene therapy strategies, wherein the manipulation of genetic material is performed to rectify or substitute malfunctioning genes accountable for the disorder, is expected to drive the corticobasal degeneration market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the corticobasal degeneration market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for corticobasal degeneration and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the corticobasal degeneration market in any manner.

Recent Developments:

• In August 2024, AC Immune SA announced that its partner Life Molecular Imaging (LMI) had received Fast Track Designation for the Tau positron emission tomography (PET) diagnostic, [18F]PI-2620, from the U.S. FDA in three neurodegenerative conditions, including Alzheimer's disease, progressive supranuclear palsy, and corticobasal degeneration.
• In March 2024, CurePSP announced that it had awarded its latest Pathway and Pipeline Grants, totaling more than $400,000. The study will lead to a better understanding of the basic neurobiology of progressive supranuclear palsy and corticobasal degeneration, as well as the identification of biomarkers to improve diagnosis and treatment.

Key Highlights:

• Corticobasal degeneration often affects adults aged 50 to 70, with an average age of onset of 64.
• Corticobasal degeneration is predicted to affect 5 people per 100,000 in the general population, with around one new case per 100,000 people each year.
• Several studies have shown that corticobasal degeneration is more common in women.
• Corticobasal degeneration also accounts for 4-6% of patients with Parkinson's.
• Corticobasal degeneration patients have an average life expectancy of 6 to 8 years after symptoms appear.

Drugs:

Fasudil is a potent Rho-kinase (ROCK) inhibitor that is estimated to minimize wandering behaviors by enhancing blood flow in the hippocampus, a brain region important for navigation, learning, and memory. The medication is non-sedating and taken orally.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the corticobasal degeneration market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the corticobasal degeneration market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current corticobasal degeneration marketed drugs and late-stage pipeline drugs.

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report

Market Insights

• How has the corticobasal degeneration market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the corticobasal degeneration market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the corticobasal degeneration market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of corticobasal degeneration across the seven major markets?
• What is the number of prevalent cases (2018-2034) of corticobasal degeneration by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of corticobasal degeneration by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of corticobasal degeneration by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with corticobasal degeneration across the seven major markets?
• What is the size of the corticobasal degeneration patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of corticobasal degeneration?
• What will be the growth rate of patients across the seven major markets?
   

Corticobasal Degeneration: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for corticobasal degeneration drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the corticobasal degeneration market?
• What are the key regulatory events related to the corticobasal degeneration market?
• What is the structure of clinical trial landscape by status related to the corticobasal degeneration market?
• What is the structure of clinical trial landscape by phase related to the corticobasal degeneration market?
• What is the structure of clinical trial landscape by route of administration related to the corticobasal degeneration market?